This article compiles and summarizes the latest developments in cosmetics regulations in China and globally as of June 2025, covering industry news, newly issued regulations, relevant policy adjustments, and regulatory requirements. It aims to assist enterprises in ensuring compliance and keeping up with global cosmetics regulatory trends.
China
This section is divided into two main modules: Regulatory Updates and Local Developments & Industry News. The first module primarily covers the latest regulatory developments issued by national authorities such as the National Medical Products Administration (NMPA) and the National Institutes for Food and Drug Control (NIFDC). The second module compiles and summarizes cosmetics-related updates from local authorities as well as key industry news.
Regulatory Updates
China NIFDC Solicits Public Comments on Nine Draft Cosmetic Standards, Including General Rules for Physicochemical Testing Methods
On June 24, the China National Institutes for Food and Drug Control (NIFDC) issued a public consultation notice to further improve cosmetic technical standards. NIFDC has organized the drafting and revision of nine draft cosmetic standards, including: General Rules for Physicochemical Testing Methods (Draft for Comments) and its drafting notes, Testing Methods for Six Cosmetic Ingredients Including Cannabidiol (CBD) (Draft for Comments) and its drafting notes. Public comments are now being solicited. Please submit your feedback through the Cosmetic Standards Development and Revision Management System by July 15, 2025.
Cosmetic Standards Development and Revision Management System:
https://www.nifdc.org.cn/nifdc/bshff/hzhpbzh/hzhpbzhxt/index.html
https://www.nifdc.org.cn//nifdc/bshff/hzhpbzh/hzhpbzhtzgg/202506240922061614120.html
Announcement of the National Medical Products Administration on Matters Related to the Management of the "Inventory of Existing Cosmetic Ingredients" (No. 61 of 2025)
On June 24, the National Medical Products Administration (NMPA) issued this announcement to implement the Regulations on the Supervision and Administration of Cosmetics, further regulate the management of cosmetic ingredients, and encourage ingredient innovation.
- According to the Cosmetics Supervision and Administration Regulations, new cosmetic ingredients that have been registered or filed and have completed a 3-year safety monitoring period without any safety issues shall be included in the Inventory. To facilitate the management of existing cosmetic ingredients, the NMPA will manage the Inventory through two lists: List I and List II.
- List I is based on the Inventory issued by the NMPA in 2021, with the removal of the item “maximum historical usage amount in products.” The Chinese names and INCI/English names of relevant ingredients have been standardized, and the remarks for certain ingredients have been adjusted in accordance with the Safety and Technical Standards for Cosmetics.
- List II includes two new cosmetic ingredients: “N-Acetylneuraminic Acid” and“β-Alanyl-Hydroxyprolyl-Diaminobutyroyl Benzylamide.” These two new ingredients have completed the 3-year safety monitoring period after filing and have been evaluated as compliant with relevant regulatory requirements.
- The NMPA has established a dynamic adjustment mechanism for the Inventory. The Inventory will be dynamically updated, supplemented, improved, and corrected based on scientific research progress, industry development, and actual regulatory needs.
https://www.nmpa.gov.cn/xxgk/ggtg/hzhpggtg/jmhzhptg/20250624153604180.html
Notice of the National Institutes for Food and Drug Control on the Issuance of Two Technical Guidelines, Including the Guideline for the Study and Determination of the History of Safe Use of New Cosmetic Ingredients (Trial)
On June 24, the National Institutes for Food and Drug Control (NIFDC) has formulated the Guideline for the Study and Determination of the History of Safe Use of New Cosmetic Ingredients (Trial) and the Guideline for the Study and Determination of the History of Safe Consumption of New Cosmetic Ingredients (Trial).
https://www.nifdc.org.cn//nifdc/bshff/hzhpjssp/hzpsptzgg/202506241613081614732.html
Local Developments & Industry News
Anhui | Anhui Medical Products Administration Issued the Submission Guidelines for Filing Dossiers of Domestic General Cosmetics in Anhui Province
On June 10, the Anhui Medical Products Administration released the Submission Guidelines for Filing Dossiers of Domestic General Cosmetics in Anhui Province, which systematically integrates requirements related to formula submission, labeling management, filing inspection, and safety assessment for domestic general cosmetics. In addition, taking into account the actual practices of cosmetic notification in Anhui Province, the Guidelines summarize and categorize key reference documents, including a list of commonly restricted or conditionally permitted ingredients, a directory of raw materials requiring CAS numbers, and a reference table of precautionary statements.
https://mpa.ah.gov.cn/public/4140867/122912041.html
Anhui | Anhui Medical Products Administration Released the Annual Report on the Safety Status of Drugs, Medical Devices, and Cosmetics in Anhui Province (2024)
On June 12, the Anhui Medical Products Administration issued the Annual Report on the Safety Status of Drugs, Medical Devices, and Cosmetics in Anhui Province (2024). To comprehensively summarize and analyze the province’s overall safety status in 2024, the Administration organized the compilation of this report.
The main text is divided into eight chapters, covering key areas such as general overview, licensing and approval, supervision and inspection, sampling and testing, case investigation and handling, adverse reaction (event) monitoring, regulatory capacity building, emergency management, and social co-governance.
https://mpa.ah.gov.cn/public/4140867/122920231.html
Heilongjiang | Heilongjiang Medical Products Administration Solicits Public Comments on the Implementation Rules for the Public Disclosure of Administrative Penalty Information by Heilongjiang Medical Products Administration (Draft for Comments)
On June 19, the Heilongjiang Medical Products Administration issued a notice to solicit public comments on the Implementation Rules for the Public Disclosure of Administrative Penalty Information by Heilongjiang Medical Products Administration (Draft for Comments), which were drafted to further standardize the management of administrative penalty information disclosure. The public consultation period is from June 19 to July 19, 2025.
https://mpa.hlj.gov.cn/mpa/yjzj/yjzjly.shtml?id=58bc319fc8774c4fa3ee08c8be4bcc62
Beijing Municipal Administration for Market Regulation and Beijing Medical Products Administration | Jointly Issued the Guidelines for the Publication of Cosmetic Advertisements in Beijing
On June 27, to support the healthy development of the cosmetics industry, regulate advertising practices, and protect the legitimate rights and interests of consumers, the Beijing Municipal Administration for Market Regulation and the Beijing Medical Products Administration jointly issued the Guidelines for the Publication of Cosmetic Advertisements in Beijing. The Guidelines outline key aspects, including the scope of application, advertising requirements, a negative list, specific requirements for advertising of children's cosmetics, and circumstances under which the Guidelines do not apply.
https://scjgj.beijing.gov.cn/zwxx/2024zcwj/202506/t20250627_4129056.html
Beijing | Notice on the Issuance of the Implementation Plan for the High-Quality Development of the Fashion Industry in Beijing (2025-2027)
On June 9, the Beijing Municipal Bureau of Economy and Information Technology, along with four other departments, jointly issued the Implementation Plan for the High-Quality Development of the Fashion Industry in Beijing (2025–2027).
With regard to cosmetics, the Plan identifies beauty and personal care brands as a key area for development. It emphasizes a focus on skincare, medical aesthetics, makeup, and fragrance, aiming to optimize the cultivation and development mechanisms for domestic brands and to encourage international luxury brands to establish R&D and manufacturing bases in Beijing. The Plan also promotes the improvement of the entire value chain of the beauty and health industry, including R&D and design, intelligent digital manufacturing, testing and inspection, experiential marketing, and platform-based trading. It encourages innovation in cosmetic raw materials, the upgrading and transformation of downstream manufacturing, and the development of personalized beauty services.
https://www.beijing.gov.cn/zhengce/gfxwj/202506/t20250611_4110943.html
Global
This section primarily covers global cosmetics-related developments for June 2025.
Europe
SCCS Issued Scientific Opinion on Prostaglandin Analogues
On June 6, the Scientific Committee on Consumer Safety (SCCS) of the European Union issued a preliminary opinion (SCCS/1680/25) on Prostaglandin Analogues: Methylamido-Dihydro-Noralfaprostal (MDN) (CAS No. 155206-01-2), Isopropyl Cloprostenate (IPCP) (CAS No. 157283-66-4) and Dechloro Dihydroxy Difluoro Ethylcloprostenolamide (DDDE) (CAS No. 1185851-52-8). The deadline for comments is set for August 18, 2025.
https://www.cirs-group.com/en/cosmetics/sccs-issued-scientific-opinion-on-prostaglandin-analogues
SAG-CS Issued Opinion on Formaldehyde Releasing Substances
In May 2025, Scientific Advisory Group of Chemical Safety of Non-food and Non-medicinal Consumer Products (SAG-CS) issued opinion on formaldehyde-releasing substances (Opinion 16). Members concluded that the current threshold of 0.05% for labelling formaldehyde-releasing preservatives was insufficient to protect consumers.
SAG-CS Issued Opinion on Homosalate in Cosmetics
In May 2025, the Scientific Advisory Group of Chemical Safety of Non-food and Non-medicinal Consumer Products (SAG-CS) issued an opinion on Homosalate in Cosmetics (Opinion 17). Members concluded that homosalate is safe at a maximum concentration of 10% in sunscreen products. An adequate analytical method appears to be available for homosalate.
https://www.cirs-group.com/en/cosmetics/uk-sag-cs-issued-opinion-on-homosalate-in-cosmetics
South America
MERCOSUR Revises List of Prohibited Substances in Cosmetics
On June 12, 2025, the MERCOSUR Secretariat issued Document No. 07/25, revising the list of substances prohibited in cosmetic products. The updated regulation takes effect immediately upon publication. Key changes include:
- Addition of New Prohibited Substances: 18 boron-containing compounds, including boron trioxide, boron oxide, and boric acid; 8 other chemical substances, such as Polyurethane-18.
- Amendments to Substance Names on the Prohibited List: The English name of 4-benciloxifenol is corrected to 4-BENZYLOXYPHENOL; The English name of 4-etoxifenol is corrected to 4-ETHOXYPHENOL.
- Removal of Substances from the Prohibited List: Benzoyl peroxide, methyl eugenol, hydroquinone (1,4-dihydroxybenzene), and azelaic acid.
- Transition Period: A 12-month transition period is granted for compliance, except for Butylphenyl Methylpropional (CAS No. 80-54-6) and Hydroxyisohexyl 3-Cyclohexene Carboxaldehyde (CAS Nos. 31906-04-4 / 51414-25-6), which are subject to immediate prohibition.
Asia
Vietnam Notifies Draft Decree on the Management of Cosmetics
On June 17, 2025, the Ministry of Health of Vietnam submitted notification G/TBT/N/VNM/349 to the WTO, announcing the proposed Draft Decree on the Management of Cosmetics. The draft decree is expected to be approved in September 2025 and come into effect on July 1, 2026. The deadline for comments is 60 days from the date of notification. The draft Decree on the Management of Cosmetics comprises 10 Chapters and 69 Articles, including: Classification and Grouping of Cosmetics, Cosmetic Product Notification, Cosmetic Manufacturing, etc.
https://www.nifdc.org.cn//nifdc/bshff/hzhpbzh/hzhpbzhtzgg/202506240922061614120.html
South Korea Proposes Amendment to the Enforcement Decree of the Cosmetics Act
On June 19, 2025, the Ministry of Food and Drug Safety (MFDS) of South Korea issued Announcement No. 2025-258, proposing an amendment to the Enforcement Decree of the Cosmetics Act and opened it for public consultation. The deadline for submitting comments is July 30, 2025.
About CIRS
The CIRS cosmetic team is dedicated to ensuring that cosmetic products meet stringent global regulatory standards. It can provide one-stop services covering the whole life-cycle of a personal care product, which includes cosmetic ingredient development, physical/chemical tests, toxicological tests (in vivo & in vitro), efficacy studies (in vivo & in vitro), ingredient registration, and product registration.
About CIRS Biotech
CIRS Biotech is a professional third-party testing organization in Hangzhou, China, established by CIRS Testing from CIRS Group and Professor Jianxin Wu’s team from China Pharmaceutical University in 2022. CIRS Biotech is providing scientific supports of cosmetic efficacy and claims for cosmetic ingredients and products. The services include in-vitro research of efficacy for cosmetic ingredients and products, in-depth research on in-vitro study method, R&D support, etc.
Our Global Compliance Services
[Regulatory Compliance Services]
- China: Compliance Consulting for Cosmetics and Ingredients
- International: Compliance Consulting for Cosmetics (EU, US, Japan, South Korea, Australia & New Zealand, ASEAN, Middle East, Mexico, Brazil, Africa)
- China and International Compliance Consulting for Disinfectants and Household Products
[Data Services]
- China: Cosmetics and Ingredients Data Services (China CosIng)
- International: Cosmetics and Ingredients Data Services covering China (including Taiwan), EU, North America, ASEAN, Japan, and South Korea (Global CosIng)
[Product Testing Services]
- Cosmetic Safety and Human Efficacy Testing
- Toxicological Safety Assessment for Cosmetic Ingredients
- In Vitro Efficacy Testing for Cosmetics and Ingredients
If you need any assistance have any questions, please get in touch with us via kexinbio@cirs-group.com.
Contact Us
Quick Navigation